Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats

American Journal of Veterinary Research

Volumn 63, Issue 8, 2002, Pages 1129-1133

  Dank, Gillian ^a   Chien, May B ^a   London, Cheryl A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; GENOMIC DNA; ONCOPROTEIN; PARAFFIN;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CAT; CONTROLLED STUDY; DNA ISOLATION; ENZYME ACTIVE SITE; EXON; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; MASTOCYTOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; SPLEEN TUMOR; TEACHING HOSPITAL; UNITED STATES; VETERINARY MEDICINE;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0036702248     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.1129     Document Type: Article

References (32)

1. Spangler WL, Culbertson MR. Prevalence and type of splenic diseases in cats: 455 cases (1985-1991). J Am Vet Med Assoc 1992;201:773-776.
2. Carpenter JL, Andrews LK, Holzworth J. Tumors and tumor like lesions. In: Holzworth J, ed. Diseases of the cat: medicine and surgery. Philadelphia: WB Saunders Co, 1987;406-596.
3. Macy DW, MacEwen EG. Mast cell tumors. In: Withrow SJ, MacEwen EG, eds. Clinical veterinary oncology. Philadelphia: JB Lippincott Co, 1989;156-166.
4. Vail DM. Mast Cell Tumors. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. Philadelphia: WB Saunders Co, 1994;192-210.
5. Liska WD, MacEwen EG, Zaki FA, et al. Feline systemic mastocytosis: a review and results of splenectomy in seven cases. J Am Anim Hosp Assoc 1979;15:589-597.
6. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-421.
7. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55:1-96.
8. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem. Cell Biol 1999;31:1037-1051.
9. d mice. Am J Pathol 1987;127:191-198.
10. v mice and their increase by bone marrow transplantation. Blood 1978;52:447-452.
11. d anemic mice. Blood 1979;53:492-497.
12. Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 1990;63:195-201.
13. Tsai M, Takeishi T, Thompson H, et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A 1991;88:6382-6386.
14. Nocka K, Buck J, Levi E, et al. Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J 1990;10:3287-3294.
15. Austen KF, Boyce JA. Mast cell lineage development and phenotypic regulation. Leuk Res 2001;25:511-518.
16. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am 2000;14:517-535.
17. Taylor ML, Dastych J, Sehgal D, et al. The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis. Blood 2001;98:1195-1199.
18. Tsujimura T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P815 generated by a point mutation. Blood 1994; 83:2619-2626.
19. Tsujimura T, Furitsu T, Morimoto M, et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995;106:377-385.
20. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand independent activation of c-kit product. J Clin Invest 1993;92:1736-1744.
21. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998;103:740-749.
22. Pignon J-M, Giraudier S, Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374-376.
23. Nagata H, Okada T, Worobec AS, et al. c-kit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 1997;113:184-186.
24. Longley BJ, Jr, Metcalfe DD, Tharp M, et al.: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999;96:1609-1614.
25. Worobec AS, Semere T, Nagata H, et al. Clinical correlates of the presence of the AspB16Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1996;83:2120-2129.
26. Buttner C, Henz BM, Welker P, et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227-1231.
27. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
28. Ma Y, Longley BJ, Wang X, et al. Clustering of activating mutations in c-KIT's juxtamembrane coding region of canine mast cell neoplasms. J Invest Dermatol 1999;112:165-170.
29. Ma Y, Cunningham ME, Wang X, et al. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999;274:13399-13402.
30. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S-4S.
31. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol 1991;96:45S-46S.
32. Longley BJ Jr, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993;328:1302-1307.